



Joint working executive summary

Project title	Executive summary of a joint-working agreement between the Yorkshire and Humber Academic Health Science Network (Y&HAHSN) and Sanofi – Improving the identification and treatment of patients with Familial Hypercholesterolaemia in primary care
Partner organisation/s	Yorkshire and Humber Academic Health Science Network Sanofi
Project rationale	<p>The Yorkshire and Humber Academic Health Science Network (Y&H AHSN) is dedicated to improving healthcare, driving wealth creation and promoting research participation across the region. Y&H AHSN has numerous member organisations which cover 22 CCGs.</p> <p>Sanofi and Y& H AHSN are working in partnership under a joint working agreement to facilitate better identification of patients within primary care who may be at risk of having Familial Hypercholesterolaemia (FH) or high cardiovascular (CV) risk. The project will consist of a baseline audit to identify patients who have or may be at risk of FH or high CV risk using an audit system provided by a third party supplier. Patient reviews will follow which will be delivered by a third party supplier with support from specialist NHS personnel and the majority of these will take place in primary care. Any clinical interventions that take place will be implemented in line with local guidelines and pathways. The audit tool will be utilised at various time intervals to measure the impact of the project.</p> <p>Patient and healthcare professional questionnaires will be used to measure the impact of any teaching or training interventions.</p> <p>Progress of the project will be tracked by a designated project team which will consist of members both from Y&H AHSN and Sanofi. The overall project delivery will be overseen by a project manager.</p>



Project period	Anticipated Finish date for the project is Quarter 2 2020.
Project objectives	<p>For the Patient</p> <ul style="list-style-type: none">• Delivery of optimised care in line with local guidelines (and in line with nationally accepted guidance)• More prompt assessment and earlier access to the most appropriate treatments• A more convenient service model which will improve patient experience and understanding of the disease <p>For the NHS</p> <ul style="list-style-type: none">• Better identification and data recording of patients with FH or high CV risk• Specific training for healthcare professionals within primary care to enhance their skills when dealing with a patient who has FH and / or high CV risk• Improvement in unplanned admissions and local medicines optimisation <p>For Sanofi</p> <ul style="list-style-type: none">• Increased appropriate use of medicines, which may include Sanofi medicines <p>The results of the project will be written up and published to enable the learnings from the project to be shared.</p>
Contact details	<p>Y&H AHSN: Navigation Court Calder Park Wakefield WF2 7BJ 01924 664506</p> <p>Sanofi: Fleur Chandler Head of Market Access Sanofi 410 Thames Valley Park Drive Reading Berks, RG6 1PT gb-marketaccess@sanofi.com</p>

